<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826422</url>
  </required_header>
  <id_info>
    <org_study_id>DHA/EPA in Dunchenne</org_study_id>
    <secondary_id>180058</secondary_id>
    <nct_id>NCT01826422</nct_id>
  </id_info>
  <brief_title>Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients</brief_title>
  <official_title>Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinaci贸n de Investigaci贸n en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Rehabilitacion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinaci贸n de Investigaci贸n en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of docosahexaenoic fatty acid and
      eicosapentaenoic fatty acid supplementation for six months on the inflammation state as well
      as the process of muscular regeneration and the metabolic disorders like obesity and insulin
      resistance in patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy
      (DMB) compared to those receiving placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DMD and DMB are X-linked diseases caused by mutations in the DMD gene, these mutations have
      important functional and structural consequences in skeletal muscle. In muscle fiber is
      observed inflammation and necrosis as a result of lost regenerative capacity. The muscle
      fibers can be replaced by connective and adipose tissue. In a previous study the
      investigators identified that 50% of Duchenne and Becker patients in the range of thirteen
      years old have obesity. In addition, these patients (N=66) have hyperinsulinemia (53.7%) and
      insulin resistance (48.5%). It is well known that obesity, hyperinsulinemia and insulin
      resistance have a inflammatory background.

      It has been demonstrated that eicosapentaenoic fatty acid (EPA) and docosahexaenoic fatty
      acid (DHA) exhibit anti-inflammatory properties and have beneficial effects on obesity,
      hyperinsulinemia and insulin resistance in children and adolescents.

      Objective: Determine the effect of EPA and DHA on inflammation, obesity and insulin
      resistance in patients with DMD/DMB compared to those receiving placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Composition (Body Fat)</measure>
    <time_frame>At baseline and at months 3 and 6 of supplementation.</time_frame>
    <description>We observed changes in body composition such as total body fat by Dual X-ray Absorptiometry (DXA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean Mass</measure>
    <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
    <description>We observed changes in body composition such as total lean mass by Dual X-ray Absorptiometry (DXA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Body Mass Index</measure>
    <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
    <description>We measured weight, height by anthropometric to calculate the body mass index (body mass index).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose in Serum</measure>
    <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
    <description>A fasting blood sample was taken; serum glucose (mg/dL) levels were measured by the glucose-oxidase method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin in Blood</measure>
    <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
    <description>A fasting blood sample was taken; insulin was quantified utilizing a commercial kit, that is based on the radioimmunoanalysis method (RIA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarkers (TNF-A)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>Plasma cytokine TNF-A was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarkers (IL-1)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>Plasma cytokine IL-1 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarkers (IL-6)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3, and 6 of supplementation.</time_frame>
    <description>Plasma cytokine IL-6 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarkers (IL-10)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>Plasma cytokine IL-10 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarker (IL-6 Expression)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-6 from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarker (TNF-A Expression)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The messenger ribonucleic acid (mRNA) expression of cytokines TNF-A from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Biomarker (IL-1 Expression)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-1 was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Degeneration (Creatinine Kinase)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The concentration in serum of CK was determined by chemiluminescent immunometric assay in U/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Degeneration (MMP9)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 of supplementation.</time_frame>
    <description>Plasma matrix metalloproteinase 9 (MMP9) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Degeneration (sFas)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The concentration in plasma of soluble Fas (sFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Degeneration (Receptor of Fas)</measure>
    <time_frame>At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>The concentration in plasma of the receptor o Fas (rFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Regeneration (VEGF)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>Vascular endothelial growth factor (VEGF) was quantified using enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Muscle Regeneration (FGF)</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
    <description>Plasma marker of regeneration fibroblast growth factor basic (FGF) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incorporation of DHA in the Erythrocytes</measure>
    <time_frame>Time Frame: At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
    <description>The percentage of DHA in the membrane of erythrocytes was determinated by gas chromatography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incorporation of EPA in the Erythrocytes</measure>
    <time_frame>Time Frame: At baseline, at 1, 2, 3, 4, 5, and 6</time_frame>
    <description>The percentage of EPA in the membrane of erythrocytes was determinated by gas chromatography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>EPA and DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA and DHA</intervention_name>
    <description>Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.</description>
    <arm_group_label>EPA and DHA</arm_group_label>
    <other_name>omega 3 fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent and assent by the patient and both parents or guardian.

          -  Patients with clinical diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker
             Muscular Dystrophy (DMB)

          -  Patients were not under treatment with corticosteroids

        Exclusion Criteria:

          -  Patients decided to withdraw from the study

          -  Consumption of dietary supplements containing polyunsaturated fatty acids omega 3.

          -  With hypersensitivity to fish oil.

          -  Patients with respiratory and gastrointestinal problems. Medical responsible
             assessment the presence of respiratory and gastrointestinal problems.

          -  Patients with difficulty swallowing food, including those who have the difficulty
             ingesting oil capsules.

          -  Gastrostomy fed patients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maricela Rodriguez-Cruz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit of Medical Researcha in Nutrition, Pediatric Hospital, IMSS.</name>
      <address>
        <city>Mexico city</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Cruz Guzm谩n Odel R, Ch谩vez Garc铆a AL, Rodr铆guez-Cruz M. Muscular dystrophies at different ages: metabolic and endocrine alterations. Int J Endocrinol. 2012;2012:485376. doi: 10.1155/2012/485376. Epub 2012 Jun 3.</citation>
    <PMID>22701119</PMID>
  </reference>
  <reference>
    <citation>Rodr铆guez-Cruz M, Sanchez R, Escobar RE, Cruz-Guzm谩n Odel R, L贸pez-Alarc贸n M, Bernabe Garc铆a M, Coral-V谩zquez R, Matute G, Vel谩zquez Wong AC. Evidence of Insulin Resistance and Other Metabolic Alterations in Boys with Duchenne or Becker Muscular Dystrophy. Int J Endocrinol. 2015;2015:867273. doi: 10.1155/2015/867273. Epub 2015 May 19.</citation>
    <PMID>26089900</PMID>
  </reference>
  <results_reference>
    <citation>Rodr铆guez-Cruz M, Cruz-Guzm谩n ODR, Almeida-Becerril T, Sol铆s-Serna AD, Atilano-Miguel S, S谩nchez-Gonz谩lez JR, Barbosa-Cort茅s L, Ru铆z-Cruz ED, Huicochea JC, C谩rdenas-Conejo A, Escobar-Cedillo RE, Yam-Ontiveros CA, Ric谩rdez-Marcial EF. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial. Clin Nutr. 2017 Sep 23. pii: S0261-5614(17)31343-2. doi: 10.1016/j.clnu.2017.09.011. [Epub ahead of print]</citation>
    <PMID>28987470</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <results_first_submitted>January 23, 2017</results_first_submitted>
  <results_first_submitted_qc>July 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinaci贸n de Investigaci贸n en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Maricela Rodriguez Cruz</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Becker Muscular Dystrophy</keyword>
  <keyword>Omega 3</keyword>
  <keyword>Eicosapentaenoic fatty acid</keyword>
  <keyword>Docosahexaenoic fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study were enrolled DMD/DMB patients from four Hospitals from Mexico city.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>EPA and DHA</title>
          <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
        </group>
        <group group_id="P2">
          <title>Sunflower Oil</title>
          <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EPA and DHA</title>
          <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
        </group>
        <group group_id="B2">
          <title>Sunflower Oil</title>
          <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="3.1"/>
                    <measurement group_id="B2" value="8.6" spread="2.9"/>
                    <measurement group_id="B3" value="8.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Composition (Body Fat)</title>
        <description>We observed changes in body composition such as total body fat by Dual X-ray Absorptiometry (DXA).</description>
        <time_frame>At baseline and at months 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition (Body Fat)</title>
          <description>We observed changes in body composition such as total body fat by Dual X-ray Absorptiometry (DXA).</description>
          <units>g/Kg of body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.1" lower_limit="84.7" upper_limit="530.4"/>
                    <measurement group_id="O2" value="232.7" lower_limit="122.5" upper_limit="542.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.2" lower_limit="95.2" upper_limit="540.2"/>
                    <measurement group_id="O2" value="274.8" lower_limit="124.4" upper_limit="547.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.9" lower_limit="98.0" upper_limit="535.0"/>
                    <measurement group_id="O2" value="298.2" lower_limit="120.7" upper_limit="567.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lean Mass</title>
        <description>We observed changes in body composition such as total lean mass by Dual X-ray Absorptiometry (DXA).</description>
        <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Mass</title>
          <description>We observed changes in body composition such as total lean mass by Dual X-ray Absorptiometry (DXA).</description>
          <units>g/kg of body weight</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774.7" lower_limit="429.1" upper_limit="857.3"/>
                    <measurement group_id="O2" value="662.4" lower_limit="413.3" upper_limit="841.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769.6" lower_limit="427.0" upper_limit="846.0"/>
                    <measurement group_id="O2" value="647.7" lower_limit="420.4" upper_limit="827.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="772.4" lower_limit="419.9" upper_limit="851.5"/>
                    <measurement group_id="O2" value="630.6" lower_limit="420.1" upper_limit="827.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="757.7" lower_limit="421.0" upper_limit="838.7"/>
                    <measurement group_id="O2" value="627.7" lower_limit="414.5" upper_limit="835.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="755.7" lower_limit="416.9" upper_limit="855.0"/>
                    <measurement group_id="O2" value="605.7" lower_limit="414.0" upper_limit="823.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768.6" lower_limit="423.6" upper_limit="829.8"/>
                    <measurement group_id="O2" value="617.7" lower_limit="433.0" upper_limit="811.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.7" lower_limit="426.2" upper_limit="849.9"/>
                    <measurement group_id="O2" value="606.2" lower_limit="398.1" upper_limit="813.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anthropometric Measurement: Body Mass Index</title>
        <description>We measured weight, height by anthropometric to calculate the body mass index (body mass index).</description>
        <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Anthropometric Measurement: Body Mass Index</title>
          <description>We measured weight, height by anthropometric to calculate the body mass index (body mass index).</description>
          <units>g/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="20.4" upper_limit="97.0"/>
                    <measurement group_id="O2" value="72.7" lower_limit="1.8" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="9.6" upper_limit="97.2"/>
                    <measurement group_id="O2" value="78.3" lower_limit="3.9" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" lower_limit="3.7" upper_limit="97.6"/>
                    <measurement group_id="O2" value="83.2" lower_limit="5.4" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="15.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="82.2" lower_limit="4.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" lower_limit="14.8" upper_limit="95.9"/>
                    <measurement group_id="O2" value="73.7" lower_limit="9.8" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="3.4" upper_limit="96.5"/>
                    <measurement group_id="O2" value="75.3" lower_limit="7.7" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="9.5" upper_limit="96.8"/>
                    <measurement group_id="O2" value="73.6" lower_limit="5.3" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose in Serum</title>
        <description>A fasting blood sample was taken; serum glucose (mg/dL) levels were measured by the glucose-oxidase method.</description>
        <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose in Serum</title>
          <description>A fasting blood sample was taken; serum glucose (mg/dL) levels were measured by the glucose-oxidase method.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" lower_limit="77.0" upper_limit="98.0"/>
                    <measurement group_id="O2" value="89.0" lower_limit="76.0" upper_limit="121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="79.0" upper_limit="98.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="81.0" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="74.0" upper_limit="93.0"/>
                    <measurement group_id="O2" value="89.0" lower_limit="79.0" upper_limit="107.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="61.0" upper_limit="95.0"/>
                    <measurement group_id="O2" value="86.8" lower_limit="79.5" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="72.0" upper_limit="97.0"/>
                    <measurement group_id="O2" value="87.0" lower_limit="82.0" upper_limit="107.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="76.0" upper_limit="99.0"/>
                    <measurement group_id="O2" value="89.8" lower_limit="75.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="76.0" upper_limit="98.0"/>
                    <measurement group_id="O2" value="88.0" lower_limit="78.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin in Blood</title>
        <description>A fasting blood sample was taken; insulin was quantified utilizing a commercial kit, that is based on the radioimmunoanalysis method (RIA).</description>
        <time_frame>At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin in Blood</title>
          <description>A fasting blood sample was taken; insulin was quantified utilizing a commercial kit, that is based on the radioimmunoanalysis method (RIA).</description>
          <units>碌U/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.1" upper_limit="28.4"/>
                    <measurement group_id="O2" value="20.9" lower_limit="3.0" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="5.5" upper_limit="38.5"/>
                    <measurement group_id="O2" value="17.8" lower_limit="4.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="3.6" upper_limit="30.8"/>
                    <measurement group_id="O2" value="18.5" lower_limit="2.4" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="3.2" upper_limit="34.1"/>
                    <measurement group_id="O2" value="18.0" lower_limit="3.8" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="2.0" upper_limit="24.2"/>
                    <measurement group_id="O2" value="21.0" lower_limit="3.9" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="2.3" upper_limit="25.9"/>
                    <measurement group_id="O2" value="17.7" lower_limit="4.2" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="1.5" upper_limit="28.9"/>
                    <measurement group_id="O2" value="18.8" lower_limit="1.9" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarkers (TNF-A)</title>
        <description>Plasma cytokine TNF-A was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarkers (TNF-A)</title>
          <description>Plasma cytokine TNF-A was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="50.01"/>
                    <measurement group_id="O2" value="-1.45" spread="37.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.04" spread="28.04"/>
                    <measurement group_id="O2" value="-21.01" spread="37.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.79" spread="32.69"/>
                    <measurement group_id="O2" value="-37.76" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.78" spread="26.62"/>
                    <measurement group_id="O2" value="-60.56" spread="18.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarkers (IL-1)</title>
        <description>Plasma cytokine IL-1 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarkers (IL-1)</title>
          <description>Plasma cytokine IL-1 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="53.77"/>
                    <measurement group_id="O2" value="21.74" spread="60.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="60.69"/>
                    <measurement group_id="O2" value="-2.49" spread="76.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.84" spread="34.96"/>
                    <measurement group_id="O2" value="-9.89" spread="63.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.04" spread="31.56"/>
                    <measurement group_id="O2" value="-10.97" spread="70.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarkers (IL-6)</title>
        <description>Plasma cytokine IL-6 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3, and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarkers (IL-6)</title>
          <description>Plasma cytokine IL-6 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="43.80"/>
                    <measurement group_id="O2" value="0.08" spread="63.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.57" spread="44.95"/>
                    <measurement group_id="O2" value="-3.6" spread="41.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.33" spread="35.17"/>
                    <measurement group_id="O2" value="-16.61" spread="46.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.33" spread="20.89"/>
                    <measurement group_id="O2" value="-24.83" spread="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarkers (IL-10)</title>
        <description>Plasma cytokine IL-10 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarkers (IL-10)</title>
          <description>Plasma cytokine IL-10 was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.66" spread="115.80"/>
                    <measurement group_id="O2" value="-8.89" spread="68.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="114.65"/>
                    <measurement group_id="O2" value="-21.16" spread="50.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.49" spread="171.49"/>
                    <measurement group_id="O2" value="-39.91" spread="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.85" spread="173.87"/>
                    <measurement group_id="O2" value="-41.21" spread="52.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarker (IL-6 Expression)</title>
        <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-6 from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarker (IL-6 Expression)</title>
          <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-6 from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="2.7"/>
                    <measurement group_id="O2" value="2.45" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="1.95"/>
                    <measurement group_id="O2" value="5.33" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.88"/>
                    <measurement group_id="O2" value="7.82" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.26"/>
                    <measurement group_id="O2" value="3.5" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.39"/>
                    <measurement group_id="O2" value="9.5" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarker (TNF-A Expression)</title>
        <description>The messenger ribonucleic acid (mRNA) expression of cytokines TNF-A from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR)</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarker (TNF-A Expression)</title>
          <description>The messenger ribonucleic acid (mRNA) expression of cytokines TNF-A from circulating leucocytes was determined by quantifying the real-time polymerase chain reaction (PCR)</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="2.6"/>
                    <measurement group_id="O2" value="1.15" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="2.6"/>
                    <measurement group_id="O2" value="1.05" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.07"/>
                    <measurement group_id="O2" value="2.12" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="2.0"/>
                    <measurement group_id="O2" value="2.27" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.43"/>
                    <measurement group_id="O2" value="0.52" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Biomarker (IL-1 Expression)</title>
        <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-1 was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Biomarker (IL-1 Expression)</title>
          <description>The messenger ribonucleic acid (mRNA) expression of cytokines IL-1 was determined by quantifying the real-time polymerase chain reaction (PCR).</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.96"/>
                    <measurement group_id="O2" value="1.7" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.24"/>
                    <measurement group_id="O2" value="1.08" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.51"/>
                    <measurement group_id="O2" value="0.86" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.16"/>
                    <measurement group_id="O2" value="0.66" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.4"/>
                    <measurement group_id="O2" value="1.93" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Degeneration (Creatinine Kinase)</title>
        <description>The concentration in serum of CK was determined by chemiluminescent immunometric assay in U/L.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Degeneration (Creatinine Kinase)</title>
          <description>The concentration in serum of CK was determined by chemiluminescent immunometric assay in U/L.</description>
          <units>percentage of change respect at basal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.30" spread="38.56"/>
                    <measurement group_id="O2" value="8.82" spread="52.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.10" spread="58.23"/>
                    <measurement group_id="O2" value="-9.95" spread="55.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="38.24"/>
                    <measurement group_id="O2" value="0.75" spread="44.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="42.67"/>
                    <measurement group_id="O2" value="-1.52" spread="33.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Degeneration (MMP9)</title>
        <description>Plasma matrix metalloproteinase 9 (MMP9) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in ng/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Degeneration (MMP9)</title>
          <description>Plasma matrix metalloproteinase 9 (MMP9) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in ng/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" lower_limit="-84.0" upper_limit="58.5"/>
                    <measurement group_id="O2" value="-13.0" lower_limit="-74.4" upper_limit="168.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-58.8" upper_limit="315.6"/>
                    <measurement group_id="O2" value="47.7" lower_limit="-73.0" upper_limit="274.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" lower_limit="-61.9" upper_limit="92.0"/>
                    <measurement group_id="O2" value="53.5" lower_limit="-59.1" upper_limit="526.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" lower_limit="-58.0" upper_limit="37.3"/>
                    <measurement group_id="O2" value="39.9" lower_limit="-40.1" upper_limit="443.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Degeneration (sFas)</title>
        <description>The concentration in plasma of soluble Fas (sFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Degeneration (sFas)</title>
          <description>The concentration in plasma of soluble Fas (sFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="-87.4" upper_limit="33.0"/>
                    <measurement group_id="O2" value="15.8" lower_limit="-49.8" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="-89.0" upper_limit="53.5"/>
                    <measurement group_id="O2" value="15.8" lower_limit="-29.7" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="-88.8" upper_limit="47.1"/>
                    <measurement group_id="O2" value="14.5" lower_limit="-53.5" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="-89.5" upper_limit="157.7"/>
                    <measurement group_id="O2" value="20.7" lower_limit="-34.7" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Degeneration (Receptor of Fas)</title>
        <description>The concentration in plasma of the receptor o Fas (rFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Degeneration (Receptor of Fas)</title>
          <description>The concentration in plasma of the receptor o Fas (rFas) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="-45.3" upper_limit="95.7"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-62.5" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-54.3" upper_limit="47.7"/>
                    <measurement group_id="O2" value="-10.1" lower_limit="-56.5" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" lower_limit="-44.2" upper_limit="28.8"/>
                    <measurement group_id="O2" value="-16.3" lower_limit="-58.5" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" lower_limit="-54.4" upper_limit="14.9"/>
                    <measurement group_id="O2" value="-30.0" lower_limit="-61.2" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Regeneration (VEGF)</title>
        <description>Vascular endothelial growth factor (VEGF) was quantified using enzyme linked immunosorbent assay (ELISA).</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Regeneration (VEGF)</title>
          <description>Vascular endothelial growth factor (VEGF) was quantified using enzyme linked immunosorbent assay (ELISA).</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" lower_limit="-89.6" upper_limit="75.3"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-75.3" upper_limit="182.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-47.0" upper_limit="123.3"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-46.3" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" lower_limit="-44.2" upper_limit="28.8"/>
                    <measurement group_id="O2" value="-16.3" lower_limit="-58.5" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" lower_limit="-40.0" upper_limit="26.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="-39.0" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Muscle Regeneration (FGF)</title>
        <description>Plasma marker of regeneration fibroblast growth factor basic (FGF) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Muscle Regeneration (FGF)</title>
          <description>Plasma marker of regeneration fibroblast growth factor basic (FGF) was determined by enzyme-linked immunosorbent assay (ELISA) with a multiplex kit in picograms/mL.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" lower_limit="-76.2" upper_limit="133.6"/>
                    <measurement group_id="O2" value="-37.3" lower_limit="-79.7" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-47.0" upper_limit="123.3"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-46.3" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" lower_limit="-69.8" upper_limit="186.2"/>
                    <measurement group_id="O2" value="-57.1" lower_limit="-89.2" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" lower_limit="-87.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="-70.9" lower_limit="-80.0" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incorporation of DHA in the Erythrocytes</title>
        <description>The percentage of DHA in the membrane of erythrocytes was determinated by gas chromatography.</description>
        <time_frame>Time Frame: At baseline and at months 1, 2, 3, 4, 5 and 6 of supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incorporation of DHA in the Erythrocytes</title>
          <description>The percentage of DHA in the membrane of erythrocytes was determinated by gas chromatography.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="-34.4" upper_limit="721.9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-79.0" upper_limit="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="-63.2" upper_limit="364.1"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-78.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.4" lower_limit="-43.7" upper_limit="1385.8"/>
                    <measurement group_id="O2" value="-17.4" lower_limit="-89.9" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.6" lower_limit="-49.5" upper_limit="1100.6"/>
                    <measurement group_id="O2" value="5.6" lower_limit="-59.4" upper_limit="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.6" lower_limit="-35.2" upper_limit="1163.8"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-77.7" upper_limit="125.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.4" lower_limit="-82.7" upper_limit="2117.6"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-73.8" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incorporation of EPA in the Erythrocytes</title>
        <description>The percentage of EPA in the membrane of erythrocytes was determinated by gas chromatography.</description>
        <time_frame>Time Frame: At baseline, at 1, 2, 3, 4, 5, and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPA and DHA</title>
            <description>Patients received 2.9 g of EPA and DHA per day in 10 capsules (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U</description>
          </group>
          <group group_id="O2">
            <title>Sunflower Oil</title>
            <description>Patients received capsules of placebo sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The placebo capsules contain each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incorporation of EPA in the Erythrocytes</title>
          <description>The percentage of EPA in the membrane of erythrocytes was determinated by gas chromatography.</description>
          <units>percentage of change respect at basal</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.0" lower_limit="4.0" upper_limit="604.7"/>
                    <measurement group_id="O2" value="-11.8" lower_limit="-87.63" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.4" lower_limit="-10.7" upper_limit="656.3"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-87.6" upper_limit="274.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.6" lower_limit="168.6" upper_limit="1185.1"/>
                    <measurement group_id="O2" value="-19.5" lower_limit="-91.0" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.7" lower_limit="-86.7" upper_limit="999.3"/>
                    <measurement group_id="O2" value="-20.9" lower_limit="-80.2" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480.6" lower_limit="23.4" upper_limit="2356.3"/>
                    <measurement group_id="O2" value="-5.4" lower_limit="-81.0" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 after supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.4" lower_limit="-51.8" upper_limit="1174.4"/>
                    <measurement group_id="O2" value="-53.1" lower_limit="-77.2" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Between-groups analysis (omega 3 vs placebo) at 3 and 6 months.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One patient presented vomiting and diarrhea, the patient had three evacuations during the night in a period of 3 hours and vomiting occurred for a period of 10 minutes. These complications occurred only once in the first month of supplementation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EPA and DHA</title>
          <description>Supplementation of 2.9 g / d of EPA and DHA will be provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
EPA and DHA: Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U.</description>
        </group>
        <group group_id="E2">
          <title>Sunflower Oil</title>
          <description>Supplementation of placebo with sunflower fatty at doses of 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil and so will not expected to produce anti-inflammatory or insulin sensitivity effects.
Placebo Comparator: Sunflower oil; the placebo capsules will also contain sunflower oil. Each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Gastrointestinal</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting and diarrhea</sub_title>
                <description>One patient presented vomiting and diarrhea, the patient had three evacuations and one time of vomiting.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations:
The sample size was not completed mainly because patients were not eligible for inclusion.
It was not possible to standardize the technical procedures for DNA fragmentation evaluation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Maricela Rodriguez-Cruz</name_or_title>
      <organization>IMSS</organization>
      <phone>5256276900 ext . 22483</phone>
      <email>maricela.rodriguez.cruz@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

